GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aytu BioPharma Inc (LTS:0A8M) » Definitions » Price-to-Free-Cash-Flow

Aytu BioPharma (LTS:0A8M) Price-to-Free-Cash-Flow : N/A (As of Dec. 16, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Aytu BioPharma Price-to-Free-Cash-Flow?

As of today (2024-12-16), Aytu BioPharma's share price is $1.4603. Aytu BioPharma's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.36. Hence, Aytu BioPharma's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Aytu BioPharma's Price-to-Free-Cash-Flow or its related term are showing as below:

During the past 13 years, Aytu BioPharma's highest Price-to-Free-Cash-Flow Ratio was 4.47. The lowest was 1.27. And the median was 1.96.

LTS:0A8M's Price-to-Free-Cash-Flow is not ranked *
in the Drug Manufacturers industry.
Industry Median: 25.82
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Aytu BioPharma's Free Cash Flow per Share for the three months ended in Sep. 2024 was $-0.15. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-0.36.

During the past 12 months, the average Free Cash Flow per Share Growth Rate of Aytu BioPharma was -150.60% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was 79.90% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 76.00% per year.

During the past 13 years, Aytu BioPharma's highest 3-Year average Free Cash Flow per Share Growth Rate was 93.10% per year. The lowest was 62.00% per year. And the median was 80.95% per year.


Aytu BioPharma Price-to-Free-Cash-Flow Historical Data

The historical data trend for Aytu BioPharma's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aytu BioPharma Price-to-Free-Cash-Flow Chart

Aytu BioPharma Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Aytu BioPharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.84 1.94 1.38 - -

Competitive Comparison of Aytu BioPharma's Price-to-Free-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, Aytu BioPharma's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aytu BioPharma's Price-to-Free-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aytu BioPharma's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Aytu BioPharma's Price-to-Free-Cash-Flow falls into.



Aytu BioPharma Price-to-Free-Cash-Flow Calculation

Aytu BioPharma's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=1.4603/-0.356
=N/A

Aytu BioPharma's Share Price of today is $1.4603.
Aytu BioPharma's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.36.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Aytu BioPharma  (LTS:0A8M) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Aytu BioPharma Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Aytu BioPharma's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Aytu BioPharma Business Description

Traded in Other Exchanges
Address
7900 East Union Avenue, Suite 920, Denver, CO, USA, 80237
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.

Aytu BioPharma Headlines

No Headlines